ARF1 and neoplasm: These results demonstrated that myeloid cells were polarized into M1 pro‐inflammatory types and DCs were activated with enhanced antigen‐presenting ability after DU101 and DU102, the Arf1 inhibitors programmed myeloid subsets into a proinflammatory phenotype that is characteristic of an inflamed tumor microenvironment (TME).